MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
Sign Up to like & getrecommendations! Published in 2021 at "Future oncology"
DOI: 10.2217/fon-2020-1048
Abstract: Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been… read more here.
Keywords: myelofibrosis previously; danazol patients; patients myelofibrosis; jaki ... See more keywords